- NJ Bio and Charles River have partnered to provide a full suite of services for antibody drug conjugate (ADC) development and manufacturing.
- The alliance is designed to improve ADC development outcomes and accelerate time-to-market for clients.
NJ Bio and Charles River Laboratories have entered a strategic alliance to enhance and streamline the development and manufacturing of antibody drug conjugates (ADCs) for their clients. The partnership will integrate both companies’ complementary capabilities, covering early development, optimisation, and manufacturing, enabling a more cohesive and efficient service offering for ADC projects.
Bringing ADCs to market requires advanced expertise across a range of disciplines, including the synthesis of cytotoxic payloads, development of linkers, conjugation processes, and thorough preclinical and clinical testing. Through this alliance, clients benefit from Charles River’s expertise in discovering and engineering antibodies, paired with NJ Bio’s strengths in synthesising and manufacturing linkers, payloads, and ADCs.
Charles River, which has previously received industry recognition for its contributions to ADC research and development, will offer specialised support in antibody, oncology, and immunology studies. “This alliance will accelerate the progression of ADCs from concept to clinical candidate,” said a representative from Charles River, emphasising the value of combining both companies’ resources.
For its part, NJ Bio, based in Princeton, New Jersey, is a contract research organisation (CRO) with extensive experience in the GMP manufacturing of payloads, linkers, and ADCs. NJ Bio’s history of supporting clients through various stages of ADC development, including early-phase discovery and preclinical batch production, aligns well with the goals of the partnership.
Read about ADC Antibody Drug Conjugates CDMO Market 2024 Here.
Overview of outsourcing trends 
